Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Juliana Schwaab

Showing results (1-10 of 79) with videos related to

Pageof 8
Sort By:
Frontiers in Immunology|June 29, 2026
Biological functions and clinical efficacy of IL-5/IL-5Rα-targeted therapies across eosinophilia-associated diseasesJohannes Lübke, Andreas Reiter, Juliana Schwaab
Current Hematologic Malignancy Reports|July 22, 2024
Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicalsJohannes Lübke, Georgia Metzgeroth, Andreas Reiter, et al.
Acta Haematologica|February 3, 2018
Routine Screening for KIT M541L Is Not Warranted in the Diagnostic Work-Up of Patients with HypereosinophiliaYvette Hoade, Georgia Metzgeroth, Juliana Schwaab, et al.
The Journal of Allergy and Clinical Immunology|August 25, 2015
Expression of programmed cell death ligand-1 in mastocytosis correlates with disease severityAnja Rabenhorst, Silke Leja, Juliana Schwaab, et al.
Annals of Hematology|November 6, 2019
Magnetic resonance imaging reveals distinct bone marrow patterns in indolent and advanced systemic mastocytosisPhilipp Riffel, Mohamad Jawhar, Kristina Gawlik, et al.
Haematologica|August 10, 2012
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangementsAndrew Chase, Catherine Bryant, Joannah Score, et al.
Annals of Hematology|October 22, 2013
Mast cell sarcoma mimicking metastatic colon carcinomaJuliana Schwaab, Hans Peter Horny, Jens Jonescheit, et al.
Blood Advances|January 30, 2020
Treatment-free remission in FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuationGeorgia Metzgeroth, Juliana Schwaab, Nicole Naumann, et al.
Journal of Cancer Research and Clinical Oncology|January 26, 2020
An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosisPhilipp Riffel, Juliana Schwaab, Christopher Lutz, et al.
Gastroenterology Research and Practice|September 10, 2016
Prognostic Impact of mRNA Expression Levels of HER1-4 (ERBB1-4) in Patients with Locally Advanced Rectal CancerMelanie Kripp, Kirsten Merx, Ralph Markus Wirtz, et al.
Pageof 8

Showing results (1-10 of 79) with videos related to

Sort By:
Pageof 8
Frontiers in Immunology|June 29, 2026
Biological functions and clinical efficacy of IL-5/IL-5Rα-targeted therapies across eosinophilia-associated diseasesJohannes Lübke, Andreas Reiter, Juliana Schwaab
Current Hematologic Malignancy Reports|July 22, 2024
Approach to the patient with eosinophilia in the era of tyrosine kinase inhibitors and biologicalsJohannes Lübke, Georgia Metzgeroth, Andreas Reiter, et al.
Acta Haematologica|February 3, 2018
Routine Screening for KIT M541L Is Not Warranted in the Diagnostic Work-Up of Patients with HypereosinophiliaYvette Hoade, Georgia Metzgeroth, Juliana Schwaab, et al.
The Journal of Allergy and Clinical Immunology|August 25, 2015
Expression of programmed cell death ligand-1 in mastocytosis correlates with disease severityAnja Rabenhorst, Silke Leja, Juliana Schwaab, et al.
Annals of Hematology|November 6, 2019
Magnetic resonance imaging reveals distinct bone marrow patterns in indolent and advanced systemic mastocytosisPhilipp Riffel, Mohamad Jawhar, Kristina Gawlik, et al.
Haematologica|August 10, 2012
Ruxolitinib as potential targeted therapy for patients with JAK2 rearrangementsAndrew Chase, Catherine Bryant, Joannah Score, et al.
Annals of Hematology|October 22, 2013
Mast cell sarcoma mimicking metastatic colon carcinomaJuliana Schwaab, Hans Peter Horny, Jens Jonescheit, et al.
Blood Advances|January 30, 2020
Treatment-free remission in FIP1L1-PDGFRA-positive myeloid/lymphoid neoplasms with eosinophilia after imatinib discontinuationGeorgia Metzgeroth, Juliana Schwaab, Nicole Naumann, et al.
Journal of Cancer Research and Clinical Oncology|January 26, 2020
An increased bone mineral density is an adverse prognostic factor in patients with systemic mastocytosisPhilipp Riffel, Juliana Schwaab, Christopher Lutz, et al.
Gastroenterology Research and Practice|September 10, 2016
Prognostic Impact of mRNA Expression Levels of HER1-4 (ERBB1-4) in Patients with Locally Advanced Rectal CancerMelanie Kripp, Kirsten Merx, Ralph Markus Wirtz, et al.
Pageof 8